Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT01924065

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01924065
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01924065. Randomized; double masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2017-08 (actual). Results posted on 2024-10-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Acronym
AFTER-CV
Condition
Cardioversion
Condition
Cerebrovascular Stroke
Intervention (Procedure)
Cardioversion
Intervention (Drug)
Oral Anticoagulant
Lead sponsor
Suleyman Demirel University (class: other)

Record details

Record id
cardio:ct-nct01924065
Content hash
38757747bc3dffdfcca38f52a3b7f68162e2a4c8432fa530ff9908409f8cd825